ac investment research

Should I Buy NASDAQ:VIE Stock? (3% Forecasted Return) | VIE Viela Bio Stock Forecast



We do not include potential future debt issuances as a source of liquidity because of the uncertainty of a company's ability to access debt markets in times of financial stress, even for investment-grade issuers. For instance, in the case of a proposed financing, with the intended use of proceeds to repay existing debt, we will assess a company's liquidity excluding the proposed financing until it's obtained or fully underwritten.Additionally, we exclude revolver borrowing availability that we believe would be inaccessible due to covenant constraints. For revolving credit facilities with extension options, we include the extension period(s) under sources of liquidity only if the option is at the discretion of the borrower. If lenders have the option to terminate commitments at each extension point, we only include the borrowing availability under the facility up to the first extension date. We estimate VIE Viela Bio stock forecast parameters by: Pierce Oscillators with Wilcoxon Sign-Rank Test because of strategic positioning, operational performance, organizational effectiveness, risk and financial management, and governance (3% Forecasted Return)

NASDAQ:VIE Stock Forecast (Buy or Sell) as of 22 Jun 2022 for (n+6 month)

Stock: VIE Viela Bio

Time series to forecast n: 22 Jun 2022 for (n+6 month)

x axis:Likelihood %
y axis:Potential Impact %
z axis:Color (yellow to green) Technical Analysis %

Stock Forecast Criteria and Models for VIE Viela Bio

  • We deduct reported goodwill and nonservicing intangible assets from reported equity to calculate ACE, net of any related deferred tax (i.e., by adding back the associated deferred tax liability);
  • Entities that have regulatory-approved internal market risk models but are not domiciled in Basel 2.5 jurisdictions:For banks with value at risk (VaR) models validated for general risk only, we apply a 3.0 multiplier to the regulatory capital requirement figure. This is to align the VaR charge with a one-year horizon and make it consistent with a 99.9% confidence level. The multiplier includes a 50% add-on to account for extreme (fat-tail) events in a hypothetical portfolio consisting of equities, interest rate positions, commodities, and foreign exchange.
  • The risk weight for "other items" is 50% higher than the corresponding risk weight for unsecured retail lending, except when "other items" are more than 5% of total exposures.
  • For entities not subject to a regulatory CVA charge (e.g., some securities firms or banks in non-Basel III jurisdictions) and that exceed the above thresholds, the RAC CVA charge is zero if we believe that exposures to OTC not cleared through a CCP derivatives represent only a very small fraction of derivatives exposures for the firm.
  • Interpolation is one of the methods we may use when we analyze the amount of credit enhancement associated with the rating levels between 'AAA' and 'B' for transactions in certain asset classes. For other asset classes, we create specific benchmarks, such as coverage multiples or simulated default rates, within a mathematical simulation model.
  • We assign no equity content to hybrid instruments that do not meet the requirements for high or intermediate equity content, including when issuer intent is lacking, and therefore treat these instruments as akin to debt in our analyses, where applicable.
  • The analysis of operational and administrative risks generally considers the possibility that a servicer may become unable or unwilling to perform its duties during the life of the transaction. In that vein, the analysis may consider both the potential for hiring a substitute or successor servicer and any arrangements that provide for a designated backup servicer. That portion of the analysis would typically consider the sufficiency of the servicing fee to attract a substitute, the seniority of the fee in the payment priorities, and the availability of substitute servicers.

Assumptions Underlying The Forecast Model for VIE Viela Bio

For example, if a company incurred a large working capital inflow in the fourth quarter, which more than offset working capital outflows during the first three quarters, we would use the peak working capital outflows within our A/B and A-B calculation. However, we avoid double-counting when the working capital outflow is already captured through our assumption of peak CP amount.

Frequently Asked QuestionsQ: Is VIE Viela Bio stock buy or sell?
A: We do not include potential future debt issuances as a source of liquidity because of the uncertainty of a company's ability to access debt markets in times of financial stress, even for investment-grade issuers. For instance, in the case of a proposed financing, with the intended use of proceeds to repay existing debt, we will assess a company's liquidity excluding the proposed financing until it's obtained or fully underwritten.
Q: Is VIE Viela Bio stock expected to go up?
A: Additionally, we exclude revolver borrowing availability that we believe would be inaccessible due to covenant constraints. For revolving credit facilities with extension options, we include the extension period(s) under sources of liquidity only if the option is at the discretion of the borrower. If lenders have the option to terminate commitments at each extension point, we only include the borrowing availability under the facility up to the first extension date.
Q: What is the forecast for VIE Viela Bio ?
A: For example, if a company incurred a large working capital inflow in the fourth quarter, which more than offset working capital outflows during the first three quarters, we would use the peak working capital outflows within our A/B and A-B calculation. However, we avoid double-counting when the working capital outflow is already captured through our assumption of peak CP amount.
Q: What is the consensus rating of VIE Viela Bio ?
A: The consensus rating for VIE Viela Bio is 74.
Q: What are the risks of investing VIE Viela Bio ?
A: We use risk analysis for VIE Viela Bio because of strategic positioning, operational performance, organizational effectiveness, risk and financial management, and governance


VIE Viela Bio
AC Investment Research

In our experiment, we focus on an approach known as Decision making using game theory. We apply principles from game theory to model the relationships between rating actions, news, market signals and decision making.

301 Massachusetts Avenue Cambridge, MA 02139 667-253-1000 pr@ademcetinkaya.com